Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib. (PubMed, J Clin Med) - Oct 17, 2026 - "Particular attention is given to tumor heterogeneity and the tumor microenvironment as determinants of treatment response and resistance, as well as to emerging strategies involving next-generation inhibitors, antibody-drug conjugates, immunotherapy, rational combinations, and longitudinal molecular monitoring. Collectively, the clinical development of pemigatinib, zanidatamab, and ivosidenib demonstrates the therapeutic value of matching actionable molecular alterations with mechanism-based treatments, while highlighting the need to overcome resistance and optimize treatment sequencing to achieve more durable benefit in advanced CCA."
Biomarker • IO biomarker • Journal • Review • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR2 • HER-2 • IDH1
|